HIV prevention shot delivery methods put to the test

NCT ID NCT05374525

Completed Prevention Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how to best offer cabotegravir, an HIV prevention shot, in US clinics. About 287 men and transgender men at risk for HIV took part. Researchers compared two ways of rolling out the shot to see which worked better in busy and less busy clinics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabotegravir (injectable and oral tablets)
What this could lead to: If successful, this study could show the best way to offer cabotegravir PrEP in clinics, making HIV prevention easier and more accessible for at-risk groups.
What could go wrong: This is a completed Phase 4 implementation study, not a test of the drug itself. It focuses on clinic processes, not new efficacy or safety data, so results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Los Angeles, California, 90036, United States
GSK Investigational Site

San Francisco, California, 94102, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20005, United States
GSK Investigational Site

Miami, Florida, 33140, United States
GSK Investigational Site

Orlando, Florida, 32806, United States
GSK Investigational Site

Pensacola, Florida, 32503, United States
GSK Investigational Site

Sarasota, Florida, 34237, United States
GSK Investigational Site

Bridgeport, Kansas, 06605, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Columbia, Missouri, 65212, United States
GSK Investigational Site

St Louis, Missouri, 63117, United States
GSK Investigational Site

Rochester, New York, 14607, United States
GSK Investigational Site

The Bronx, New York, 10467, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19123, United States
GSK Investigational Site

Charleston, South Carolina, 29407, United States
GSK Investigational Site

Harlingen, Texas, 78550, United States
GSK Investigational Site

Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.